HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Videotimes Technology Holdings - Expected to See Performance Decline Due to Tariff War

Pre-IPO Tong Ren Tang Healthcare Investment (PHIP Updates) - Some Points Worth the Attention

Pre-IPO Softcare (PHIP Updates) - Some Points Worth the Attention

Pre-IPO Bama Tea - The Business Model, the Challenges and the Outlook

Pre-IPO LXJ International Holdings - The Pain Points and the Outlook

Pre-IPO Kayou - The Strength of Business Model and the Potential Risks Behind

Pre-IPO Green Tea Group (PHIP Updates) - Some Points Worth the Attention

Pre-IPO Fujian Lemo IoT Technology - The Outlook for Growth and Profit Margins Is Not Optimistic

Equity Capital Markets

Boxihe Outdoor Sports Group / Equity Capital Markets

<ul>
<li>Based on the successful application of self-developed technology, Boxihe has embarked on a completely opposite path to international brands, highlighting the "cost-effectiveness" in outdoor sports industry, thus achieving high growth.</li>
<li>Creating the next blockbuster and diversifying product portfolios greatly test Boxihe’s operational capabilities, with some uncertainties. Boxihe may face the troubles of finding a new growth point in long term.</li>
<li>Performance growth could remain high in the short term. Post-money valuation after Series B Financing reached RMB2.8 billion.Valuation of Boxihe could be higher than <a href="https://www.smartkarma.com/entities/li-ning-co-ltd" target="_blank" data-smartkarma-citation="entities:6047:1" rel="noopener">Li Ning </a>but lower than <a href="https://www.smartkarma.com/entities/anta-sports-products-ltd" target="_blank" data-smartkarma-citation="entities:10261:1" rel="noopener">Anta</a>.</li>
</ul>


Based on the successful application of self-developed technology, Boxihe has embarked on a completely opposite path to international brands, highlighting the "cost-effectiveness" in outdoor sports industry, thus achieving high growth.
Creating the next blockbuster and diversifying product portfolios greatly test Boxihe’s operational capabilities, with some uncertainties. Boxihe may face the troubles of finding a new growth point in long term.
Performance growth could remain high in the short term. Post-money valuation after Series B Financing reached RMB2.8 billion.Valuation of Boxihe could be higher than Li Ning but lower than Anta.


Pre-IPO Boxihe Outdoor Sports Group - 높은 성장 뒤에 숨겨진 우려